Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

[1]  K. Schön,et al.  ADP-Ribosylation Controls the Outcome of Tolerance or Enhanced Priming Following Mucosal Immunization , 2010, The Journal of Immunology.

[2]  W. Van den Broeck,et al.  NALT (nasal cavity-associated lymphoid tissue) in the rabbit. , 2010, Veterinary Immunology and Immunopathology.

[3]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[4]  J. Remon,et al.  Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. , 2009, Vaccine.

[5]  P. Rossignol,et al.  A multifactorial strategy of pain management is associated with less pain in scheduled vaccination of children. A study realized by family practitioners in 239 children aged 4-12 years old. , 2008, Family practice.

[6]  M. Fay,et al.  Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.

[7]  S. Pizzo,et al.  Mast cell activators: a new class of highly effective vaccine adjuvants , 2008, Nature Medicine.

[8]  H. Staats,et al.  Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination , 2007, AAPS PharmSciTech.

[9]  Gideon Kersten,et al.  Needle-free vaccine delivery , 2007, Expert opinion on drug delivery.

[10]  B. Haynes,et al.  In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity , 2007, Infection and Immunity.

[11]  P. Brandtzaeg.  Induction of secretory immunity and memory at mucosal surfaces. , 2007, Vaccine.

[12]  R. Couch,et al.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. , 2007, Vaccine.

[13]  Vincent J. Sullivan,et al.  Intranasal Administration of Dry Powder Anthrax Vaccine Provides Protection Against Lethal Aerosol Spore Challenge , 2007, Human vaccines.

[14]  U. Yrlid,et al.  Regulation of intestinal immunity: Effects of the oral adjuvant Escherichia coli heat‐labile enterotoxin on migrating dendritic cells , 2007, European journal of immunology.

[15]  L. Baillie.  Past, imminent and future human medical countermeasures for anthrax , 2006, Journal of applied microbiology.

[16]  H. Iida,et al.  The Effect of Sevoflurane on Ciliary Motility in Rat Cultured Tracheal Epithelial Cells: A Comparison with Isoflurane and Halothane , 2006, Anesthesia and analgesia.

[17]  S. Vyas,et al.  Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. , 2006, Vaccine.

[18]  M. S. Williams,et al.  An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. , 2006, Vaccine.

[19]  S. Ascarateil,et al.  The use of oil adjuvants in therapeutic vaccines. , 2006, Vaccine.

[20]  J. Harkema,et al.  The Nose Revisited: A Brief Review of the Comparative Structure, Function, and Toxicologic Pathology of the Nasal Epithelium , 2006, Toxicologic pathology.

[21]  M. Neutra,et al.  TLRs Regulate the Gatekeeping Functions of the Intestinal Follicle-Associated Epithelium1 , 2006, The Journal of Immunology.

[22]  Brian R. Sloat,et al.  Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non‐anaesthetized mice , 2006, The Journal of pharmacy and pharmacology.

[23]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[24]  D. Rhee,et al.  Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide. , 2005, Biologicals : journal of the International Association of Biological Standardization.

[25]  J. Bienenstock,et al.  Bronchus‐ and nasal‐associated lymphoid tissues , 2005, Immunological reviews.

[26]  N. Lycke.  From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. , 2005, Immunology letters.

[27]  Vincent J. Sullivan,et al.  Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. , 2005, The Journal of infectious diseases.

[28]  D. R. Kockler,et al.  Trivalent Intranasal Influenza Vaccine, Live , 2004, The Annals of pharmacotherapy.

[29]  N. Lycke.  ADP‐Ribosylating Bacterial Enzymes for the Targeted Control of Mucosal Tolerance and Immunity , 2004, Annals of the New York Academy of Sciences.

[30]  R. Walker,et al.  Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  B. Haynes,et al.  A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. , 2004, Vaccine.

[32]  S. Fukuyama,et al.  NALT- versus PEYER'S-patch-mediated mucosal immunity , 2004, Nature Reviews Immunology.

[33]  R. Rappuoli,et al.  Novel Approaches to Vaccine Delivery , 2004, Pharmaceutical Research.

[34]  S. Brody.  Declining HIV rates in Uganda: due to cleaner needles, not abstinence or condoms , 2004, International journal of STD & AIDS.

[35]  Gordon Larsen,et al.  Technologies that make administration of vaccines safer. , 2004, Vaccine.

[36]  R. Couch.  Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.

[37]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[38]  B. Ivins,et al.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. , 2004, Vaccine.

[39]  R. Cox,et al.  Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.

[40]  P. Brandtzaeg.  Immunology of tonsils and adenoids: everything the ENT surgeon needs to know. , 2003, International journal of pediatric otorhinolaryngology.

[41]  E. Swiatlo,et al.  PneumococcalSurface Protein A Is Expressed In Vivo, and Antibodies to PspA AreEffective for Therapy in a Murine Model of PneumococcalSepsis , 2003, Infection and Immunity.

[42]  J. Mcghee,et al.  Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen1 , 2003, The Journal of Immunology.

[43]  A. Zuercher,et al.  Structural and functional differences between putative mucosal inductive sites of the rat , 2002, European journal of immunology.

[44]  I. Aaberge,et al.  Influence of Intravenous Anesthesia on Mucosal and Systemic Antibody Responses to Nasal Vaccines , 2002, Infection and Immunity.

[45]  S. Ascarateil,et al.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines , 2002, Expert review of vaccines.

[46]  J. Fukuda,et al.  Evaluation of interleukin 1 as a mucosal adjuvant in immunization with Streptococcus sobrinus cells by tonsillar application in rabbits. , 2002, Oral microbiology and immunology.

[47]  T. Murai,et al.  Evaluation of the In Vitro Pyrogen Test System Based on Proinflammatory Cytokine Release from Human Monocytes: Comparison with a Human Whole Blood Culture Test System and with the Rabbit Pyrogen Test , 2002, Clinical and Vaccine Immunology.

[48]  W. Lednar,et al.  New developments in influenza vaccine technology: a potential new prevention strategy for employers and managed care organizations. , 2002, American Journal of Managed Care.

[49]  P. O'Byrne,et al.  Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[50]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[51]  H. Liao,et al.  Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization , 2002, Journal of Virology.

[52]  S. Davis,et al.  Clearance characteristics of chitosan based formulations in the sheep nasal cavity. , 2001, International journal of pharmaceutics.

[53]  M. Marinaro,et al.  Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. , 2000, The American journal of pathology.

[54]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[55]  J. Mcghee,et al.  Mucosally Induced Immunoglobulin E-Associated Inflammation in the Respiratory Tract , 2000, Infection and Immunity.

[56]  F. Ennis,et al.  IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. , 1999, Journal of immunology.

[57]  C. Dinarello.  Cytokines as endogenous pyrogens. , 1999, The Journal of infectious diseases.

[58]  I. Mcdougall,et al.  Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. , 1999, Nuclear medicine communications.

[59]  J. Mcghee,et al.  A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. , 1998, Journal of immunology.

[60]  B. Wahrén,et al.  Prevention of Experimental Autoimmune Neuritis by Nasal Administration of P2 Protein Peptide 57-81 , 1998, Journal of neuropathology and experimental neurology.

[61]  F. Shi,et al.  Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA , 1997, Journal of Neuroimmunology.

[62]  M. Russell,et al.  Nasal Lymphoid Tissue (NALT) as a Mucosal Immune Inductive Site , 1997, Scandinavian journal of immunology.

[63]  H. Link,et al.  Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. , 1997, Clinical immunology and immunopathology.

[64]  H. Staats,et al.  Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. , 1997, AIDS research and human retroviruses.

[65]  W. Kuis,et al.  Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S. Gizurarson,et al.  Intranasal booster vaccination against diphtheria and tetanus in man. , 1997, Vaccine.

[67]  L. McDaniel,et al.  Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection , 1997, Infection and immunity.

[68]  W. Foster,et al.  Importance of airway blood flow on particle clearance from the lung. , 1996, Journal of applied physiology.

[69]  J. Smith,et al.  Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. , 1996, Stem cells.

[70]  H. Staats,et al.  Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). , 1996, Journal of immunology.

[71]  J. W. Smith,et al.  Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects , 1996, The oncologist.

[72]  R. Holmdahl,et al.  Mucosal tolerance and suppression of collagen‐induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184‐198 of bovine type II collagen (CII) expressing a dominant T cell epitope , 1996, Clinical and experimental immunology.

[73]  M. Marinaro,et al.  Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. , 1995, Journal of immunology.

[74]  D. Nash.  Inappropriate administration of DT/DTP vaccines. , 1995, Journal of Family Practice.

[75]  J G Hamilton,et al.  Needle phobia: a neglected diagnosis. , 1995, The Journal of family practice.

[76]  M. Marinaro,et al.  Mucosal immunity to infection with implications for vaccine development. , 1994, Current opinion in immunology.

[77]  J. Marshall,et al.  Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. , 1994, Journal of immunology.

[78]  C. Czuprynski,et al.  Species-specific binding of IL-1, but not the IL-1 receptor antagonist, by fibroblasts. , 1994, Cytokine.

[79]  J. Mcghee,et al.  Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant , 1993, Infection and immunity.

[80]  S. Nourshargh,et al.  Comparative responses of human and rabbit interleukin-1 in vivo: effect of a recombinant interleukin-1 receptor antagonist. , 1992, Immunology.

[81]  M. Iriki,et al.  Action site of circulating interleukin-1 on the rabbit brain , 1991, Brain Research.

[82]  T. Watanabe,et al.  Central action sites of interleukin‐1 beta for inducing fever in rabbits. , 1990, The Journal of physiology.

[83]  C. Libert,et al.  Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice , 1990, European journal of immunology.

[84]  M. J. Staruch,et al.  The adjuvanticity of interleukin 1 in vivo. , 1983, Journal of immunology.

[85]  Myron M. Levine,et al.  Can needle-free administration of vaccines become the norm in global immunization? , 2003, Nature Medicine.

[86]  E. Swiatlo,et al.  Pneumococcal Surface Protein A Is Expressed In Vivo, and Antibodies to PspA Are Effective for Therapy in a Murine Model of Pneumococcal Sepsis , 2003 .

[87]  T. Montag,et al.  Comparative study of rabbit pyrogen test and human whole blood assay on human serum albumin. , 2002, ALTEX.

[88]  Paul Flecknell,et al.  Replacement, reduction and refinement. , 2002, ALTEX.

[89]  C. J. Clements,et al.  Technologies to Improve Immunisation Safety , 2001, Drug safety.

[90]  L. Simonsen,et al.  Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. , 1999, Bulletin of the World Health Organization.

[91]  M. Russell,et al.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system , 1997, Immunologic research.

[92]  B. Prakken.  Peptide induced nasal tolerance for a mycobacterial hsp60 T cell epitope in rats suppresses both adjuvant arthritis and non-mycobacterially induced arthritis. , 1997 .

[93]  A. Nash,et al.  Parameters related to the application of recombinant ovine interleukin-1 beta as an adjuvant. , 1995, Vaccine.

[94]  A. J. Daniels.  Perspectives on needle phobia. , 1995, Journal of Family Practice.

[95]  H. Staats,et al.  Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. , 1990, Intervirology.

[96]  W. Fiers,et al.  Response of murine cell lines to an IL-1/IL-2-induced factor in a rat/mouse T hybridoma (PC60): differential induction of cytokines by human IL-1 alpha and IL-1 beta and partial amino acid sequence of rat GM-CSF. , 1990, Lymphokine research.